The KRYSTAL-1 Clinical Trial (NCT03785249) recruited 116 NSCLC patients who had K-Ras G12C mutation and had previously been treated with both chemotherapy and immunotherapy. Here, KRAS is linked to non-small cell lung carcinoma.